These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 34887643)

  • 1. Hepatocellular carcinoma locoregional therapies: Outcomes and future horizons.
    Makary MS; Ramsell S; Miller E; Beal EW; Dowell JD
    World J Gastroenterol; 2021 Nov; 27(43):7462-7479. PubMed ID: 34887643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies.
    Makary MS; Khandpur U; Cloyd JM; Mumtaz K; Dowell JD
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32679897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Image-guided percutaneous locoregional therapies for hepatocellular carcinoma.
    Chevallier O; Zhao K; Marinelli B; Yarmohammadi H
    Chin Clin Oncol; 2023 Apr; 12(2):17. PubMed ID: 37081710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma.
    Abdel-Rahman OM; Elsayed Z
    Cochrane Database Syst Rev; 2016 Feb; 2():CD011313. PubMed ID: 26905230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.
    Poon RT; Fan ST; Tsang FH; Wong J
    Ann Surg; 2002 Apr; 235(4):466-86. PubMed ID: 11923602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Update on Embolization Therapies for Hepatocellular Carcinoma.
    Kishore S; Friedman T; Madoff DC
    Curr Oncol Rep; 2017 Jun; 19(6):40. PubMed ID: 28421483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
    Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
    J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic disease to the liver: Locoregional therapy strategies and outcomes.
    Zane KE; Cloyd JM; Mumtaz KS; Wadhwa V; Makary MS
    World J Clin Oncol; 2021 Sep; 12(9):725-745. PubMed ID: 34631439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioembolization using yttrium-90 microspheres as bridging and downstaging treatment for unresectable hepatocellular carcinoma before liver transplantation: initial single-center experience.
    Abdelfattah MR; Al-Sebayel M; Broering D; Alsuhaibani H
    Transplant Proc; 2015 Mar; 47(2):408-11. PubMed ID: 25769582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transarterial Therapies for Hepatocellular Carcinoma: a Comprehensive Review with Current Updates and Future Directions.
    Kumar Y; Sharma P; Bhatt N; Hooda K
    Asian Pac J Cancer Prev; 2016; 17(2):473-8. PubMed ID: 26925630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in transarterial embolotherapies in the treatment of hepatocellular carcinoma.
    Lee EW; Khan S
    Clin Mol Hepatol; 2017 Dec; 23(4):265-272. PubMed ID: 29113030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.
    Llovet JM; De Baere T; Kulik L; Haber PK; Greten TF; Meyer T; Lencioni R
    Nat Rev Gastroenterol Hepatol; 2021 May; 18(5):293-313. PubMed ID: 33510460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curative-Intent Therapies in Localized Hepatocellular Carcinoma.
    O'Leary C; Mahler M; Soulen MC
    Curr Treat Options Oncol; 2020 Mar; 21(4):31. PubMed ID: 32193784
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?
    Meza-Junco J; Montano-Loza AJ; Liu DM; Sawyer MB; Bain VG; Ma M; Owen R
    Cancer Treat Rev; 2012 Feb; 38(1):54-62. PubMed ID: 21726960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
    Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
    Trials; 2012 Aug; 13():144. PubMed ID: 22913492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transarterial therapy: an evolving treatment modality of hepatocellular carcinoma.
    Jazieh KA; Arabi M; Khankan AA
    Saudi J Gastroenterol; 2014; 20(6):333-41. PubMed ID: 25434313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage locoregional therapies for recurrent hepatocellular carcinoma.
    Criss CR; Makary MS
    World J Gastroenterol; 2023 Jan; 29(3):413-424. PubMed ID: 36688022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials.
    Katsanos K; Kitrou P; Spiliopoulos S; Maroulis I; Petsas T; Karnabatidis D
    PLoS One; 2017; 12(9):e0184597. PubMed ID: 28934265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
    Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
    Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transarterial therapies in patients with hepatocellular carcinoma eligible for transarterial embolization: a US cost-effectiveness analysis.
    Patel MV; Davies H; Williams AO; Bromilow T; Baker H; Mealing S; Holmes H; Anderson N; Ahmed O
    J Med Econ; 2023; 26(1):1061-1071. PubMed ID: 37632520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.